ASSAY
Carry out the assay of heparin (2.7.5). The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The confidence limits of the estimated potency (P = 0.95) are not less than 80 per cent and not more than 125 per cent of the stated potency.

STORAGE
In an airtight container. If the substance is sterile, store in a sterile, airtight, tamper-proof container.

LABELLING
The label states:
- the number of International Units per milligram;
- the animal species of origin;
- where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.

HEPARINS, LOW-MOLECULAR-MASS

Heparina massae molecularis minoris

DEFINITION
Salts of sulfated glucosaminoglycans having a mass-average relative molecular mass less than 8000 and for which at least 60 per cent of the total mass has a relative molecular mass less than 8000. Low-molecular-mass heparins display different chemical structures at the reducing, or the non-reducing end of the polysaccharide chains.

The potency is not less than 70 IU of anti-factor Xa activity per milligram, calculated with reference to the dried substance. The ratio of anti-factor Xa activity to anti-factor IIa activity, determined as described under Assay, is not less than 1.5.

PRODUCTION
Low-molecular-mass heparins are obtained by fractionation or depolymerisation of heparin of natural origin that complies with the monograph on Heparin sodium (0333) or Heparin calcium (0332), whichever is appropriate, for parenteral administration, unless otherwise justified and authorised. For each type of low-molecular-mass heparin the batch-to-batch consistency is ensured by demonstrating, for example, that the mass-average relative molecular mass ranges lower than 8000 are not less than 75 per cent and not more than 125 per cent of the mean value stated as type specification. The same limits apply also to the ratio of anti-factor Xa activity to anti-factor IIa activity.

Nucleotide and protein impurities of the source material.
Dissolve 40 mg of the source material before fractionation in 10 mL of water R. The absorbance (2.2.25) measured at 260 nm and 280 nm is not greater than 0.20 and 0.15, respectively.

CHARACTERS
Appearance: white or almost white powder, hygroscopic. Solubility: freely soluble in water.

IDENTIFICATION
A. Nuclear magnetic resonance spectrometry (2.2.33).
Preparation: dissolve 0.200 g of the substance to be examined in a mixture of 0.2 mL of deuterium oxide R and 0.8 mL of water R.
Comparison: dissolve 0.200 g of the appropriate specific low-molecular-mass heparin reference standard in a mixture of 0.2 mL of deuterium oxide R and 0.8 mL of water R.
Operating conditions: use a pulsed (Fourier transform) spectrometer operating at 75 MHz for 1H. Record the spectra at 40 °C, using cells 5 mm in diameter. Use deuterated methanol R as internal reference at δ = 50.0 ppm.

Results: the spectrum obtained is similar to the appropriate specific low-molecular-mass heparin reference standard.
B. The ratio of anti-factor Xa activity to anti-factor IIa activity, determined as described under Assay, is not less than 1.5.
C. Size-exclusion chromatography (2.2.30).

Test solution. Dissolve 20 mg of the substance to be examined in 2 mL of the mobile phase.

Reference solution. Dissolve 20 mg of heparin low-molecular-mass for calibration CRS in 2 mL of the mobile phase.

Column: Mobile phase: 28.4 g/L solution of anhydrous sodium sulfate R adjusted to pH 5.0 using dilute sulfuric acid R.
Flow rate: 0.5 mL/min.
Detection: differential refractometer.
Injection: 25 μL.
Calibration. For detection, use a differential refractometer (RI) detector connected in series to a ultraviolet spectrophotometer (UV) set at 234 nm such that the UV monitor is connected to the column outlet, and the RI detector to the UV-monitor outlet.

It is necessary to measure the time lapse between the 2 detectors accurately, so that their chromatograms can be aligned correctly. The retention times used in the calibration must be those from the RI detector.

The normalisation factor used to calculate the relative molecular mass from the RI/UV ratio is obtained as follows: calculate the total area under the UV234 (ΣUV234) and the RI (ΣRI) curve by numerical integration over the range of interest (i.e. excluding salt and solvent peaks at the end of the chromatogram). Calculate the ratio r using the following expression:

\[
\frac{\Sigma \text{RI}}{\Sigma \text{UV234}}
\]

Calculate the factor f using the following expression:

\[
f = \frac{M_{\text{m,n}}}{M_{\text{m,cal}}}
\]

Provided the ΣUV234 and the RI responses are aligned, the relative molecular mass M at any point is calculated using the following expression:

\[
f \times \frac{\text{RI}}{\text{UV234}}
\]

The resulting table of retention times and relative molecular masses may be used to derive a calibration for the chromatographic system by fitting a suitable mathematical relationship to the data. A polynomial of the 3rd degree is recommended. It must be stressed that the extrapolation of this fitted calibration curve to higher molecular masses is not valid.

Inject 25 μL of the test solution and record the chromatogram for a period of time, ensuring complete elution of sample and solvent peaks.
The mass-average relative molecular mass is defined by the following expression:

\[ \sum \left( \frac{M_i}{R_i} \right) \frac{V_i}{\sum R_i} \]

\( R_i \) = mass of substance eluting in the fraction \( i \);
\( M_i \) = relative molecular mass corresponding to fraction \( i \).

Any low-molecular-mass heparin covered by a specific monograph complies with the requirements for identification C prescribed in the corresponding monograph. Where no specific monograph exists for the low-molecular-mass heparin to be examined, the mass-average relative molecular mass is not greater than 8000 and at least 60 per cent of the total mass has a relative molecular mass lower than 8000. In addition, the molecular mass parameters (mass-average molecular mass and mass percentages of chains comprised between specified values) correspond to that of the manufacturer’s reference preparation.

D. It gives reaction (a) of sodium or the reactions of calcium (as appropriate) (2.3.I).

**TESTS**

**pH** (2.2.3): 5.5 to 8.0.

Dissolve 0.1 g in carbon dioxide-free water R and dilute to 10 mL with the same solvent.

**Nitrogen** (2.5.9): 1.5 per cent to 2.5 per cent (dried substance).

**Calcium** (2.5.11): 9.5 per cent to 11.5 per cent (dried substance), if prepared from heparin complying with the monograph on *Heparin calcium* (0332). Use 0.200 g.

**Sodium**: 9.5 per cent to 12.5 per cent (dried substance), if prepared from heparin complying with the monograph on *Heparin sodium* (0333).

Atomic absorption spectrometry (2.2.23, Method I).

**Test solution.** Dissolve 50 mg in 0.1 M hydrochloric acid containing 1.27 mg of caesium chloride R per millilitre and dilute to 100.0 mL with the same solvent.

**Reference solutions.** Prepare reference solutions (25 ppm, 50 ppm and 75 ppm) using sodium standard solution (200 ppm Na) R diluted with 0.1 M hydrochloric acid containing 1.27 mg of caesium chloride R per millilitre.

**Source:** sodium hollow-cathode lamp.

**Wavelength:** 330.3 nm.

**Atomisation device:** flame of suitable composition (for example, 11 L of air and 2 L of acetylene per minute).

**Molar ratio of sulfate ions to carboxylate ions** (2.2.38): minimum 1.8.

For each measured figure, calculate the number of milliequivalents of sodium hydroxide added from the volume and the known concentration of the sodium hydroxide solution. Plot on a graph the figures for conductivity (as y-axis) against the figures of milliequivalents of sodium hydroxide (as x-axis). The graph will have 3, approximately linear sections: an initial steep downward slope, a middle slight rise and a final steep rise. Estimate the best straight lines through these 3 parts of the graph. At the points where the 1st and 2nd lines intersect, and where the 2nd and 3rd lines intersect, draw perpendiculars to the y-axis to estimate the milliequivalents of sodium hydroxide taken up by the sample at those points. The point where the 1st and 2nd lines intersect will give the number of milliequivalents of sodium hydroxide taken up by the sulfate groups, and the point where the 2nd and 3rd lines intersect will give the number of milliequivalents taken up by the sulfate and carboxylate groups together. The difference between the 2 will therefore give the number of milliequivalents taken up by the carboxylate groups.

**Heavy metals** (2.4.8): maximum 30 ppm.

0.5 g complies with test C. Prepare the reference solution using 1.5 mL of lead standard solution (10 ppm Pb) R.

**Loss on drying** (2.2.32): maximum 10.0 per cent, determined on 1.000 g by drying at 60 °C over diphosphorus pentoxide R at a pressure not exceeding 0.67 kPa for 3 h.

**Bacterial endotoxins** (2.6.14): less than 0.01 IU per International Unit of anti-Xa activity, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins. The addition of divalent cations may be necessary to fulfil the validation criteria.

**ASSAY**

The anticoagulant activity of low-molecular-mass heparins is determined *in vitro* by 2 assays which determine its ability to accelerate the inhibition of factor Xa (anti-Xa assay) and thrombin, factor IIa (anti-IIa assay), by antithrombin III. The International Units for anti-Xa and anti-IIa activity are the activities contained in a stated amount of the International Standard for low-molecular-mass heparin.

**Heparin low-molecular-mass for assay BPR**, calibrated in International Units by comparison with the International Standard using the 2 assays given below, is used as reference preparation.

**ANTI-FACTOR Xa ACTIVITY**

**Reference and test solutions**

Prepare 4 independent series of 4 dilutions each, of the substance to be examined and of the reference preparation of low-molecular-mass heparin in tris(hydroxymethyl)aminomethane sodium chloride buffer solution pH 7.4 R; the concentration range should be within 0.025 IU to 0.2 IU of anti-factor Xa activity per millilitre and the dilutions chosen should give a linear response when results are plotted as absorbance against log concentration.

**Procedure**

Label 16 tubes in duplicate: \( T_1, T_2, T_3, T_4 \) for the dilutions of the substance to be examined and \( S_1, S_2, S_3, S_4 \) for the dilutions of the reference preparation. To each tube add 50 \( \mu \)L of antithrombin III solution R1 and 50 \( \mu \)L of the appropriate dilution of the substance to be examined or the reference preparation. After each addition, mix but do not allow bubbles to form. Treat the tubes in the order \( S_1, S_2, S_3, S_4, T_1, T_2, T_3, T_4, T_5, T_6, S_1, S_2, S_3, S_4 \) and allow to equilibrate at 37 °C (water-bath or heating block) for 1 min and add to each tube 100 \( \mu \)L of bovine factor Xa solution R. Incubate for exactly 1 min and add 250 \( \mu \)L of chromogenic substrate R1. Stop the reaction after exactly 4 min by adding 375 \( \mu \)L of acetic acid R. Transfer the mixtures to semi-micro cuvettes and measure the absorbance (2.2.25) at 405 nm using a suitable reading device. Determine the blank amidolytic activity at the beginning and at the end of the procedure in a similar manner, using
tris(hydroxymethyl)aminomethane sodium chloride buffer solution pH 7.4 R instead of the reference and test solutions; the 2 blank values do not differ significantly. Calculate the regression of the absorbance on log concentrations of the solutions of the substance to be examined and of the reference preparation of low-molecular-mass heparins and calculate the potency of the substance to be examined in International Units of anti-factor Xa activity per millilitre using the usual statistical methods for parallel-line assays.

ANTI-FACTOR Xa ACTIVITY

Reference and test solutions

Prepare 4 independent series of 4 dilutions each, of the substance to be examined and of the reference preparation of low-molecular-mass heparin in tris(hydroxymethyl)aminomethane sodium chloride buffer solution pH 7.4 R; the concentration range should be within 0.015 IU to 0.075 IU of anti-factor Xa activity per millilitre and the dilutions chosen should give a linear response when results are plotted as absorbance against log concentration.

Procedure

Label 16 tubes in duplicate: T1, T2, T3, T4 for the dilutions of the substance to be examined and S1, S2, S3, S4 for the dilutions of the reference preparation. To each tube add 50 μL of antithrombin III solution R2 and 50 μL of the appropriate dilution of the substance to be examined or the reference preparation. After each addition, mix but do not allow bubbles to form. Treating the tubes in the order S1, S2, S3, S4, T1, T2, T3, T4, S1, S2, S3, S4, T1, T2, T3, T4, S1, S2, S3, S4, allow to equilibrate at 37 °C (water-bath or heating block) for 1 min and add to each tube 100 μL of human thrombin solution R. Incubate for exactly 4 min and add 250 μL of chromogenic substrate R2. Stop the reaction after exactly 4 min by adding 75 μL of acetic acid R. Transfer the mixtures to semi-micro cuvettes and measure the absorbance (2.2.25) at 405 nm using a suitable reading device. Determine the blank amidolytic activity at the beginning and at the end of the procedure in a similar manner, using tris(hydroxymethyl)aminomethane sodium chloride buffer solution pH 7.4 R instead of the reference and test solutions; the 2 blank values do not differ significantly. Calculate the regression of the absorbance on log concentrations of the solutions of the substance to be examined and of the reference preparation of low-molecular-mass heparins, and calculate the potency of the substance to be examined in International Units of anti-factor Xa activity per millilitre using the usual statistical methods for parallel-line assays.

LABELLING

The label states:

– the number of International Units of anti-factor Xa activity per milligram;
– the number of International Units of anti-factor Xa activity per milligram;
– the mass-average molecular mass and the percentage of molecules with defined molecular mass ranges;
– where applicable, that the contents are the sodium salt;
where applicable, that the contents are the calcium salt.

STORAGE

In an airtight tamper-proof container. If the product is sterile and free of bacterial endotoxins, store in a sterile and apyrogenic container.